Volume 26, Number 12—December 2020
Research
Trends in Population Dynamics of Escherichia coli Sequence Type 131, Calgary, Alberta, Canada, 2006–20161
Table 3
Factors associated with Escherichia coli sequence type 131 clades, Calgary, Alberta, Canada, 2006, 2012, and 2016*
Factor | Clade |
||||||
---|---|---|---|---|---|---|---|
A, n = 34 | B, n = 32 | C0, n = 5 | C1-non-M27, n = 121 | C1-M27, n = 13 | C2, n = 139 | All, n = 344 | |
QRDR mutation | |||||||
gyrA S83L | 29 (85)a,b | 2 (6)c | 2 (40)b,c | 121 (100)d | 13 (100)a,d | 139 (100)d | 306 (89) |
gyrA D87N | 5 (15)a | 0a | 1 (20)a | 121 (100)b | 13 (100)b | 139 (100)b | 279 (8) |
parC S80I | 5 (15)a | 2 (6)a | 1 (20)a | 121 (100)b | 13 (100)b | 139 (100)b | 281 (82) |
parC E84V | 1 (3)a | 0a | 1 (20)a | 121 (100)b | 13 (100)b | 139 (100)b | 275 (80) |
parE I529L |
30 (88)a |
27 (84)a |
5 (100) |
121 (100)b |
13 (100) |
139 (100)b |
335 (97) |
β-lactamase | |||||||
CTX-M-15 | 2 (6)a | 1 (3)a | 0a | 1 (1)a | 0a | 93 (67)b | 97 (28) |
CTX-M-14 | 0a | 0a | 0 | 38 (31)b | 0 | 1 (1)a | 39 (11) |
CTX-M-27 | 1 (3)a | 0a | 0 | 0a | 7 (54)b | 0a | 8 (2) |
CTX-M-55 | 2 (6) | 0 | 0 | 0 | 0 | 0 | 2 (0.6) |
CTX-M-198 | 0 | 0 | 0 | 1 (1) | 0 | 0 | 1 (0.3) |
NDM-5 | 0 | 0 | 0 | 0 | 0 | 1 (1) | 1 (0.3) |
OXA-1 | 0a | 0a | 0a | 1 (1)a | 0a | 84 (6)b | 85 (25) |
OXA-9 | 0 | 0 | 0 | 0 | 0 | 1 (1) | 1 (0.3) |
SHV-12 | 0 | 0 | 0 | 0 | 0 | 2 (1) | 2 (0.6) |
TEM-1 | 29 (85)a,b | 20 (63)a | 4 (80)a,b | 103 (85)b | 1 (8)c | 26 (19)c | 183 (53) |
TEM other | 0 | 0 | 0 | 2 (2) | 0 | 2 (1) | 4 (1) |
CMY-2 |
0 |
2 (6%) |
0 |
1 (1) |
0 |
0 |
3 (0.9) |
Aminoglycoside-modifying enzyme | |||||||
Aac(3)-IIa | 0a | 0a | 0 | 2 (1)a | 0a | 57 (41)b | 59 (17) |
Aac(3))-IId | 11 (32)a,b | 15 (47)a | 0 | 63 (52)a | 0b,c | 4 (3)c | 93 (27) |
aac(6')-Ib-cr | 0a | 0a | 0a | 2 (2)a | 0a | 84 (60)b | 86 (25) |
aadA1 | 0 | 2 6) | 0 | 0 | 0 | 4 (3) | 6 (2) |
aadA16 | 0 | 0 | 0 | 1 (1) | 0 | 1 (1) | 2 (0.6) |
aadA2 | 0a | 14 (44)b | 0 | 0a | 0a | 2 (1)a | 16 () |
aadA5 | 23 (68)a | 1 (3)b | 3 (60)a,c | 70 (58)a | 7 (54)a,c | 57 (41)c | 161 (47) |
ant(2′′)-Ia | 0 | 0 | 0 | 0 | 0 | 5 (4) | 5 (1) |
aph(3′)-Ia | 1 (3) | 2 | 0 | 1 (11) | 0 | 0 | 4 (1) |
aph(3′′)-Ib | 20 (59)a | 3 (9)b | 0 | 69 (57)a | 5 (38) | 26 (19)b | 123 (36) |
aph(3′)-IIa | 0 | 1 (3) | 0 | 1 (1) | 0 | 0 | 2 (0.6) |
Aph(6)-Ic | 0 | 1 (3) | 0 | 1 (1) | 0 | 0 | 2 (0.6) |
Aph(6)-Id |
20 (59)a |
3 (9)b |
0 |
68 (56)a |
5 (38) |
25 (18)b |
121 (35) |
Other | |||||||
qnrB | 0 | 0 | 0 | 0 | 0 | 2 (1) | 2 (0.6) |
ARR-3 | 0 | 0 | 0 | 1 (1) | 0 | 1 (1) | 2 (0.6) |
dfrA1 | 0 | 1 (3) | 0 | 0 | 0 | 0 | 1 (0.3) |
dfrA12 | 0a | 13 (41)b | 0 | 0a | 0a | 2 (1)a | 15 (4) |
dfrA14 | 1 (3) | 0 | 0 | 0 | 0 | 8 | 12 (3) |
dfrA17 | 22 (65)a | 1 (3)b | 3 (60)a | 70 (58)a | 7 (54)a | 59 (42)a | 162 (47) |
dfrA27 | 0 | 0 | 0 | 1 (1) | 0 | 1 (1) | 2 (0.6) |
dfrA5 | 0 | 1 (3) | 0 | 0 | 0 | 0 | 1 (0.3) |
sul1 | 22 (65) | 15 (47) | 3 (60) | 69 (57) | 6 (46) | 63 (45) | 178 (52) |
sul2 | 20 (59)a | 3 (9)b | 0 | 70 (58)a | 5 (38) | 28 (20)b | 126 (37) |
sul3 | 0 | 1 (3) | 0 | 0 | 0 | 0 | 1 (0.3) |
tetA | 19 (56)a | 5 (16)b | 0 | 61 (50)a | 6 (4) | 77 (55)a | 168 (49) |
tetB | 2 (6) | 3 (9) | 0 | 2 (2) | 0 | 3 (2) | 10 (3) |
*Values are no. (%). Rates followed by different superscript letters indicate significant differences between clades at the 5% level (adjusted for multiple comparisons).
1Accepted as an oral presentation for the 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, April 18–21, 2020.
2These authors contributed equally to this article.